GlobeNewswire Clinical StudiesOriginal article
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Phase 1positiveERAS-0015Positive
AI Analysis
Summary
Erasca announced updated Phase 1 data for ERAS-0015, a pan-RAS molecular glue, showing 57% uORR in 2L+ KRAS G12X pancreatic cancer patients at the recommended dose of 32 mg once daily with full dose intensity maintenance. The company plans registration-enabling studies based on these encouraging monotherapy responses.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
57% uORR in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD with median relative dose intensity of 100%
Importance:6/10
Sentiment:
0.75
pan-RASmolecular gluepancreatic cancerKRAS mutationPhase 1 dataregistration-enabling
Read the original article
Published by GlobeNewswire Clinical Studies on July 13, 2026 8:01 PM